Bicycle Therapeutics to Present Four Abstracts at ESMO Congress 2024

Bicycle Therapeutics plc, a leading pharmaceutical company known for its innovative bicyclic peptide technology, has announced the acceptance of four abstracts for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2024. The event is scheduled to be held from September 13-17 in Barcelona.

The details for the poster presentations are as follows:

The first presentation, titled “BT8009 monotherapy in enfortumab vedotin-naïve patients with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1,” will be held on Saturday, September 14, from 9-10 a.m. CEST. It will be presented by Dr. Oscar Reig Torras from the Hospital Clinic de Barcelona, with the presentation number 652P.

The second presentation, “Peripheral neuropathy following treatment with Bicycle Toxin Conjugates BT8009 or BT5528 monotherapy in patients with advanced solid tumors,” is also scheduled for Saturday, September 14, from 9-10 a.m. CEST. Dr. Bernard Doger de Spéville of START Madrid-FJD and Hospital Universitario Fundacion Jimenez Diaz will deliver this presentation, which has been assigned the number 654P.

The third presentation, titled “EphA2-targeting Bicycle Toxin Conjugate BT5528 in patients with advanced solid tumors: A phase 1/2 study,” will take place on Saturday, September 14, from 9-10 a.m. CEST. Dr. Elisa Fontana of the Sarah Cannon Research Institute UK will present this study, which has the presentation number 647P.

Lastly, the fourth presentation, “Initial results from a phase 1/2 study of BT7480, a novel Nectin-4/CD137 Bicycle Tumor-Targeted Immune Cell Agonist, in patients with advanced solid tumors,” will also be held on Saturday, September 14, from 9-10 a.m. CEST. This presentation, numbered 650P, will be given by Dr. Kyriakos P. Papadopoulos from START San Antonio.

Bicycle Therapeutics is a clinical-stage company focused on developing a new class of medicines known as Bicycle molecules. These molecules are fully synthetic short peptides linked by small molecule scaffolds to form two loops, which stabilize their structural geometry. This unique design enhances target binding with high affinity and selectivity, making them promising candidates for drug development.

The company is currently evaluating several therapeutic candidates in clinical trials. Zelenectide pevedotin (formerly BT8009) is a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen. Another candidate, BT5528, is a BTC molecule aimed at EphA2, a historically challenging target. Additionally, BT7480 is a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) that targets Nectin-4 and activates CD137.

Apart from these candidates, Bicycle Therapeutics is also developing Bicycle Radio Conjugates (BRCs) for radiopharmaceutical applications. The company is exploring the potential of its Bicycle technology through various partnerships to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with essential functions and leadership team members based in Cambridge, Massachusetts. The company continues to push the boundaries of medical science with its novel approach to drug development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!